Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
40 hedge funds and large institutions have $366M invested in Evelo Biosciences, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 3 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11% more capital invested
Capital invested by funds: $329M → $366M (+$37.1M)
8% more funds holding
Funds holding: 37 → 40 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.13M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.16M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$745K |
| 4 |
State Street
Boston,
Massachusetts
|
+$714K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$703K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.88M |
| 2 |
Goldman Sachs
New York
|
-$286K |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$121K |
| 4 |
Barclays
London,
United Kingdom
|
-$24K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.7K |
EVLO Hedge Fund Activity: Q4 2018 in Review
40 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q4 2018, worth a combined $366M — up 11% from $329M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVLO positions and 3 closed out — a net gain of 3 holders — while 21 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $4.13M. The largest seller was ARK Investment Management, exiting entirely with an estimated $2.88M sold.
- 40 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q4 2018, up from 37 in Q3 2018.
- Funds reported $366M of Evelo Biosciences, Inc. Common Stock stock for Q4 2018, up 11% quarter-over-quarter.
- 6 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q4 2018 and 3 closed out, a net change of +3 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q4 2018 was BlackRock, an estimated $4.13M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q4 2018 was ARK Investment Management, an estimated $2.88M sold.
Based on aggregated 13F filings for Q4 2018.